- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CannTrust Shares Tumble After Pricing of Public Offering
An investment firm executive told Bloomberg the pricing of the offer from the marijuana firm is “a lot to ask.”
Shares of Canadian cannabis producer CannTrust Holdings (NYSE:CTST,TSX:TRST) dipped following the pricing of a public offering led by US banks.
The company finished the trading session on Thursday (May 2) with a drop in value of 13.06 percent in New York, closing at a price of US$5.59.
CannTrust priced its offering at US$5.50 per share for total gross proceeds of US$170 million.
In Toronto, shares of CannTrust also declined by double digits. CannTrust finished the day with a price of C$7.58 per share, representing a 12.57 percent loss in value.
“In connection with the offering, the company and the selling shareholders have granted to the underwriters a 30 day option to purchase up to an additional 4,636,363 and 818,182 common shares, respectively, at the public offering price, less the underwriting discount,” CannTrust indicated.
CannTrust originally announced the offering on April 22 and confirmed the book-running managers for the deal included top US banks such as BofA Merrill Lynch, a division of Bank of America (NYSE:BAC), and Citigroup (NYSE:C).
The rest of the underwriters are Credit Suisse Securities, Jefferies (NYSE:JEF), Canaccord Genuity (TSE:CF,OTC Pink:CCORF) and RBC Capital Markets, a division of Royal Bank of Canada (NYSE:RC,TSX:RC).
CannTrust expects the transaction to close on Monday (May 6) and will use the proceeds from the deal for general business operations, including its pursuit of a good manufacturing process certification.
Justin Ort, partner at Measure8 Venture Partners, told Bloomberg the offer is too big. His firm is now shorting CannTrust, according to the report.
“As it turns out, a US$200 million offering on a US$650 million market cap is a lot to ask and investors demanded a big discount,” Ort said.
In February, CannTrust became the fourth Canadian marijuana firm to reach the New York Stock Exchange.
“There’s no doubt in my mind that investors all around the world, in particular institutional investors, have an increasing awareness and willingness to enter the cannabis space,” Peter Aceto, CEO of CannTrust, previously told the Investing News Network.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.